Showing 1521-1530 of 10035 results for "".
Re-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumaRevance Data, AD Updates, FDA Actions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-revance-data-ad-updates-fda-actions/18463/A US District Court judge blocks Stratus Pharmaceuticals of Miami and Sonar Products of Carlstadt, NJ from selling substandard dermatological products. Newly identified mutations in a gene called CARD11 may lead to atopic dermatitis. Surprising new evidence suggests atopic dermatitis is associated wRhofade Approved, Sun Leaves Acne Behind, Radiesse Turns 10
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rhofade-approved-sun-leaves-acne-behind-radiesse-turns-10/18552/The FDA has approved Allergan's Rhofade (Oxymetazoline 1%) cream for the topical treatment of persistent facial erythema associated with rosacea in adults. New research from Olay in collaboration with personal genetics company 23andMe shows that taking care of the skin may be the key to looking upProtecting Assets in a Divorce
https://practicaldermatology.com/topics/practice-management/protecting-assets-in-a-divorce/18771/Statistics show that half of marriages end in divorce. Financial consequences can be significant. OJM Group principal David Mandell, JD, MBA, discusses how physicians can protect their assets in the pre-marital and the marital stages in the event of a divorce. Always contact local counsel before taValeant Acquires Salix; Actavis Changing Name
https://practicaldermatology.com/series/dermwire-tv/valeant-acquires-salix-actavis-changing-name/18963/Valeant expands its portfolio with the acquisition of GI market leader Salix. Actavis divests Doryx and considers a name change to Allergan. Kythera acquires rights for investigational hair therapies. And Cynosure's 532nm laser delivery system is FDA cleared for PicoSure.Otezla Approved for Plaque Psoriasis
https://practicaldermatology.com/topics/psoriasis/dermiretv-otezla-approved-for-plaque-psoriasis/19031/In this week's edition of DermWireTV from the publishers of Practical Dermatology® magazine and DermWire.com, a look at Celgene's Otezla for psoriasis--the first PDE4 inhibitor approved for plaque psoriasis. Plus, Ranbaxy's new dosage strengths of Absorica (isotretinoin), and Galderma's search for p"Atopic Dermatitis in Diverse Skin Tones" Drs. Shahriari and Bhutani
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/atopic-dermatitis-in-diverse-skin-tones-drs-shahriari-and-bhutani/24542/Drs. Mona Shahriari and Tina Bhutani provide a comprehensive overview of managing atopic dermatitis (AD) in patients with skin of color, addressing unique challenges and considerations. To access the full video and more, join YoungMD Connect member for free 90-day trial with code Free90. Continue leOrigins of AD: Recent Advances
https://practicaldermatology.com/issues/april-2025/origins-of-ad-recent-advances/35586/This paper reviews a study by Yadev et al. and further investigates the role of transient receptor potential ankyrin 1 (TRPA1) in the pathogenesis of atopic dermatitis (AD).Step Therapy Reform Advocates Seek to Spread Awareness of Proposed Law
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/step-therapy-reform-advocates-seek-to-spread-awareness-of-proposed-law/33160/The Safe Step Act would stop insurance companies under certain circumstances from requiring alternative medications before covering biologics.Analysis Evaluates Risks of Cardiovascular Events Among Biologics for Psoriatic Diseases
https://practicaldermatology.com/series/dermwire-tv/analysis-evaluates-risks-of-cardiovascular-events-among-biologics-for-psoriatic-diseases/32412/In this week's DermwireTV, a new analysis evaluates the risks of major adverse cardiovascular events among patients treated with biologics for psoriatic diseases; a phase 3 clinical trial examines the use of nemolizumab in adults with prurigo nodularis; and the president of Journey Medical discusses